Here are five insights:
1. The company encourages collaboration between the FDA and accrediting organizations to pave a regulatory path for stem cell treatments.
2. Currently, the FDA guidance on human cells, tissues or cellular or tissue-based products, reads that adipose-derived stem cells from a patient should be regulated in the same vein as a manufactured drug.
3. The drug approval process could take as long as 15 years however, so some argue this would greatly bar patients from accessing stem cell therapies in the United States.
4. Therefore, StemGenex recommends adult adipose-derived stem cell therapies should be regulated by standards similar to the American Association of Blood Banks. The AABB standards are built on quality, scientific research and patient safety.
5. StemGenex additionally proposes stem cell treatment providers register in a national directory.
More articles on devices:
Zimmer Biomet, Medtronic, Xtant Medical & more: 9 key notes
B. Braun, Trendlines partner on ApiFix investment — 4 takeaways
7 new spine, orthopedic device launches & releases — Nov. 23, 2016
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
